Synonym
Product Category
Product Code
CAS Number
MDL Number
Pubchem CID
Reaxys RN
Lenvatinib, E7080
API & Intermediates
KAPI0F15
417716-92-8
MFCD16038644
9823820
12096874
.png)
Lenvatinib (also known as E7080) is an orally active inhibitor of multiple receptor tyrosine kinases including VEGF, FGF and SCF receptors used for the treatment of certain kinds of thyroid cancer, and potentially for other cancers as well.
E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. [1]
Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase. [2]
Multikinase inhibitors: a new option for the treatment of thyroid cancer. [3]
References:
[1] J.Matsui, et al, Int. J. Cancer, 2008, 122(3), pp 664-671.
[2] J.Matusui, et al, Clin. Cancer Res., 2008, 14(17), pp 5459-5465.
[3] M.L.Gild, et al, Nature Rev. Endocrinol., 2011, 7, pp 617-624.
Signal Word
Hazard Statements
Precautionary Statements
HS Code
RIDADR
Legal Information
Not classified as a dangerous goods
2933998090
NONH for all modes of transport
Sales restrictions may apply.
1. Product Specification
2. Safety Data Sheet
Available on request.
Please inquire for pricing and availability of this product by writing email to sales@kumidas.com.